Board of Directors


Alistair Macdonald


Alistair is a seasoned pharma executive with more than 25 years of experience in the industry, across manufacturing, consultancy, business and corporate development, data management and clinical operations. Until April 2022 Alistair was CEO of leading, integrated CRO Syneos Health Inc. a role which he held for 6 years. Syneos was the result of a combination of inVentiv Health and INC Research in 2017, of which Alistair was CEO. Alistair led the merger that formed Syneos, which brought together approximately 24,000 employees serving customers in 110 countries with innovative, end-to-end solutions to accelerate their clinical development and commercialisation timelines. Prior to becoming CEO of INC Research, Alistair led multiple functions including Global Business Development and Marketing, Alliances Development and Delivery, Global Oncology, and Clinical Development Services.

Alistair has served as Chair of ACRO, the Association of Clinical Research Organisations, having been on its board for approximately seven years, and is Board Member of the Medicines Discovery Catapult.

Alistair received his Masters degree from Cranfield University, and Batchelors degree from Plymouth University.

Martin Gouldstone

Chief Executive Officer

Martin brings 30 years corporate finance and business development experience in the CRO, healthcare and pharmaceutical sectors to his role as CEO at Oncimmune. Most recently, Martin was a Global SVP Business Development at Owkin, where he managed all of the commercial teams in the USA and Europe and led new strategic research partnerships. Over the last few years, Martin was Chief Business Officer at Sensyne Health where he helped to drive growth with particular focus on expanding reach in the US market and Pharmaceutical sector; Global SVP at Syneos One and Head of Capital Solutions for Syneos Healthcare where he developed and led Capital Solutions service; Chief Business Officer at BenevolentAI where he was responsible for all commercial activities. He was previously a Partner at Results Healthcare, where he co-led the healthcare practice;Head of Lifesciences in the UK for BDO, the Lead for the M&A process in Europe for Quintiles, and Business Development and Licensing Lead at Confirmant, Pharmacopeia, Sareum. He has extensive experience buying and selling multi-billion dollar deals across Europe and the US, architecting end to end portfolio out-sourcing deals, and negotiating multi-year research partnerships. Currently, Martin is a Non-Executive Board Director for Open Orphan Plc and sits on the Board of Trustees of Orthopaedic Research UK. He holds a BSc in Genetics and has completed a range of post graduate management courses.

John Goold

Independent Non-Executive Director

John qualified as a chartered accountant in London with Touche Ross in 1996, before a 25-year career in the City raising growth capital and advising small- and mid-cap companies. John initially started out in corporate finance, before moving into equity sales and corporate broking where he spent most of his career. John has helped to raise over £5bn for his clients, much of which was while he was Chief Executive of Zeus Capital for over ten years. John has recently become Chief Executive Officer of Kelso Group Holdings plc, which is listed on the Main Market Standard Segment of the London Stock Exchange.

Dr Sally Waterman

Senior Independent Non Executive Director

Sally has more than 30 years’ experience as a senior executive and director in multiple early stage biopharmaceutical companies and service providers with roles leading R&D, operations and corporate development. She has developed and implementing strategies for growth and been involved in multiple M&A transactions and IPOs. In her R&D roles Sally has led in-house and virtual teams developing small molecules and biologics for a wide range of indications. She has worked closely with numerous contract research and development organisations spanning all aspects of drug development from lead selection to clinical trials.  Sally’s previous roles include R&D Director at KS Biomedix and Protherics and, more recently, Chief Operating Officer at Abzena and Medherant.  She is currently a non-executive director and chair of Magnitude Biosciences, a specialist CRO which used the nematode worm C.elegans to rapidly screen compounds for their impact on longevity and diseases of ageing, and a non-executive director of Cumulus Oncology, an oncology company creator.